Evaluating future Alzheimer’s disease p-Tau 181 and ApoE4 immunoassays for amyloid detection

Full poster title: Revamping Alzheimer's disease diagnostics: Evaluating future IVD plasma p-Tau 181 and ApoE4 immunoassays for amyloid detection in a multi-center study reflective of routine clinical practice.

Early detection of amyloid pathology is a critical step in the Alzheimer's disease patient journey. Blood-based biomarkers have emerged as powerful tools in accurately identifying individuals' amyloid pathology. This poster shares findings from a study that investigated the clinical performance of plasma tau phosphorylated at threonine 181 (pTau181) in combination with plasma apolipoprotein E4 (ApoE4) as a potential diagnostic test to detect amyloid pathology.